Clinical Management in Asthmatic Patients Attended in the Influential Area of Hospital Universitario Virgen de la Victoria
Photo by Olia Nayda
Andalusian Public Foundation for Research in Malaga in Biomedicine and Health (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud) is commencing recruitment for the clinical trial of the Clinical Management in Asthmatic Patients Attended in the Influential Area of Hospital Universitario Virgen de la Victoria, Málaga.
The condition is Asthma.
A new clinical trial is recruiting patients in the following locations: Spain.
The trial officially began on the November 1, 2020 and is planned to complete on June 30, 2021.
This evidence raises the need to determine the assistance quality care in asthma population in the influential area of Hospital Universitario Virgen de la Victoria through the assistance quality care indicators established by GEMA guidelines. The aim of this study is to obtain clinical data that allow to assess assistance quality degree in order to find improvement opportunities to achieve a better control of asthmatic patients within this influential area.
Asthma is a heterogenic chronic disease characterized by acute symptomatic episodes of varying severity, including intermittently inflammation and narrowing of the airways in the lungs. The prevalence of this disease is high as affects more than 300 million people worldwide, which varies by country. In Spain, the prevalence it is estimated to be around 5%, ranged between 1% in Huelva and 4,7% in Albacete, according with the European Community Respiratory Survey (ECRHS), and seems to be increased due to a higher rate of asthma diagnosis1.
The study will be performed in Hospital Virgen de la Victoria, which it's the reference hospital that usually attends the asthma population of its influential area. Only patients that meet the eligibility criteria will be included in the study, and it is planned that a total estimation of 300 patients with asthma diagnose will be included in it. The whole patients will be recruited by the site investigator and collaborators, who will conduct the subject's medical chart review. Before the patient's study inclusion, the investigator team must have been obtained the signed informed consent (appendix 3) of each patient recruited and according to ICH GCP and to local legal requirements.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04653116
